News | June 29, 2022
Glenmark Pharmaceuticals expand its OTC portfolio
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
First and only PARP inhibitor to improve invasive disease-free survival in patients
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Bringing next-gen cannabinoid therapeutics to cancer patients
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
Subscribe To Our Newsletter & Stay Updated
